No, Augmentin Should Not Be Prescribed for Possible STIs
Augmentin (amoxicillin-clavulanate) is not a recommended treatment for sexually transmitted infections and should not be used for this indication. The CDC STI treatment guidelines consistently recommend azithromycin or doxycycline as first-line therapy for chlamydia, and ceftriaxone-based regimens for gonorrhea—Augmentin appears in neither category 1.
Why Augmentin Is Inappropriate
Guideline-Based Recommendations
The most recent CDC guidelines establish clear first-line treatments for common STIs:
For Chlamydia:
- Azithromycin 1 g orally as a single dose OR
- Doxycycline 100 mg orally twice daily for 7 days 1
For Gonorrhea:
- Ceftriaxone 125-250 mg IM (with dosing based on body weight in newer guidelines) 2
- Historically combined with azithromycin or doxycycline for presumptive chlamydia coverage 1
For Non-Gonococcal Urethritis:
- Same regimens as chlamydia (azithromycin or doxycycline) 3
The Evidence Gap
While limited older research suggests amoxicillin-clavulanate may have some activity against chlamydia 4 and gonorrhea 5, 6, these studies are from the 1980s-1990s and do not supersede current guideline recommendations. Notably:
- The 1993 CDC guidelines mention amoxicillin (not Augmentin) only in the context of retesting after treatment—suggesting it as an inferior option 7
- No subsequent CDC guidelines (1998,2006,2010) include amoxicillin-clavulanate as a recommended or alternative regimen 1, 8, 1, 8, 3
- The FDA label for Augmentin does not list STIs as an approved indication 9
Critical Clinical Pitfalls
Using Augmentin for presumed STIs creates multiple problems:
- Inadequate coverage: Augmentin lacks reliable activity against the most common STI pathogens by current standards
- Resistance concerns: Gonorrhea has developed extensive resistance to penicillins and cephalosporins; using suboptimal therapy accelerates this
- Missed treatment opportunity: Patients may not return for follow-up, leaving them with persistent, untreated infection
- Complications risk: Untreated chlamydia and gonorrhea lead to pelvic inflammatory disease, infertility, ectopic pregnancy, and chronic pelvic pain 1, 8
- Ongoing transmission: Inadequate treatment allows continued spread to sexual partners
The Correct Approach
When STI is suspected but the specific pathogen is unknown:
- Treat presumptively for both gonorrhea AND chlamydia if testing is unavailable or patient may not return 1
- Use ceftriaxone 250 mg IM PLUS azithromycin 1 g orally (or doxycycline 100 mg twice daily for 7 days)
- This dual therapy approach is explicitly recommended in guidelines because coinfection rates are high 1
If only chlamydia is suspected (e.g., in populations with low gonorrhea prevalence):
- Azithromycin 1 g single dose (best for compliance concerns) OR
- Doxycycline 100 mg twice daily for 7 days (equally effective, less expensive) 1
Partner treatment is essential: All sexual partners from the preceding 60 days should receive empiric treatment with the same regimen 3
Special Considerations
- Pregnancy: Azithromycin is preferred for chlamydia; ceftriaxone remains appropriate for gonorrhea 7
- Compliance concerns: Single-dose azithromycin is superior when adherence to multi-day regimens is questionable 1
- Fluoroquinolone resistance: Avoid quinolones for gonorrhea due to widespread resistance 8
The bottom line: Stick to evidence-based, guideline-concordant therapy. Augmentin has no role in STI management in 2024.